RxDoctor Payments Data

Marcia Ryder

Nurse Practitioner · Syracuse, NYNPI 1164405213

Payments from drug & device makers

$6,492in general payments, 2019–2025

Across 78 payments — averaging $83.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Access Vascular Inc$3K
  • Amgen$1K
  • AstraZeneca$584
  • Bayer$548
  • Ardelyx, Inc.$221
  • Novo Nordisk$141
  • plus $486 from 8 others

What the payments were for

  • Speaking & faculty fees$2,00031%
  • Travel & lodging$1,21319%
  • Food & beverage$3,27951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,492 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$16,146
Medicare patients
78
Services billed
417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide31$83,872
FarxigaDapagliflozin Propanediol51$59,334
KerendiaFinerenone40$37,846
Lanthanum Carbonate16$31,313
JardianceEmpagliflozin27$29,750
LokelmaSodium Zirconium Cyclosilicate38$12,590
Potassium Citrate ErPotassium Citrate108$12,348
Sirolimus11$8,810
VeltassaPatiromer Calcium Sorbitex16$7,352
Calcitriol525$5,794
Nifedipine ErNifedipine192$5,473
Sevelamer Carbonate36$4,131
Calcium Acetate41$3,920
Torsemide220$3,671
Doxazosin Mesylate209$3,537

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$584$71,92389 claims
BayerKerendia$548$37,84640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →